Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Chimeric Antigen Receptor (CAR)-T Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size and forecasts, in consumption value ($ Million), 2018-2029
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Chimeric Antigen Receptor (CAR)-T Cell Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Autolus Therapeutics, CARsgen Therapeutics, Juno Therapeutics, Sorrento Therapeutics and bluebird bio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Chimeric Antigen Receptor (CAR)-T Cell Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Chimeric Antigen Receptor (CAR)-T Cell Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Chimeric Antigen Receptor (CAR)-T Cell Therapy, with revenue, gross margin and global market share of Chimeric Antigen Receptor (CAR)-T Cell Therapy from 2018 to 2023.
Chapter 3, the Chimeric Antigen Receptor (CAR)-T Cell Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Chimeric Antigen Receptor (CAR)-T Cell Therapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Chimeric Antigen Receptor (CAR)-T Cell Therapy.
Chapter 13, to describe Chimeric Antigen Receptor (CAR)-T Cell Therapy research findings and conclusion.
This report is a detailed and comprehensive analysis for global Chimeric Antigen Receptor (CAR)-T Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size and forecasts, in consumption value ($ Million), 2018-2029
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Chimeric Antigen Receptor (CAR)-T Cell Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Autolus Therapeutics, CARsgen Therapeutics, Juno Therapeutics, Sorrento Therapeutics and bluebird bio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Chimeric Antigen Receptor (CAR)-T Cell Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Abecma
- Breyanzi
- Kymriah
- Tecartus
- Yescarta
- Others
- Hospital
- Diagnostic Center
- Other
- Autolus Therapeutics
- CARsgen Therapeutics
- Juno Therapeutics
- Sorrento Therapeutics
- bluebird bio
- CELGENE CORPORATION
- Eureka Therapeutics
- Avacta Life Sciences
- Calyxt
- Celyad Oncology SA
- Fortress Biotech
- IMMUNE THERAPEUTICS
- Gilead Sciences
- Novartis AG
- Alaunos Therapeutics
- Poseida Therapeutics
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Chimeric Antigen Receptor (CAR)-T Cell Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Chimeric Antigen Receptor (CAR)-T Cell Therapy, with revenue, gross margin and global market share of Chimeric Antigen Receptor (CAR)-T Cell Therapy from 2018 to 2023.
Chapter 3, the Chimeric Antigen Receptor (CAR)-T Cell Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Chimeric Antigen Receptor (CAR)-T Cell Therapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Chimeric Antigen Receptor (CAR)-T Cell Therapy.
Chapter 13, to describe Chimeric Antigen Receptor (CAR)-T Cell Therapy research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Chimeric Antigen Receptor (CAR)-T Cell Therapy
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Chimeric Antigen Receptor (CAR)-T Cell Therapy by Type
1.3.1 Overview: Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type in 2022
1.3.3 Abecma
1.3.4 Breyanzi
1.3.5 Kymriah
1.3.6 Tecartus
1.3.7 Yescarta
1.3.8 Others
1.4 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market by Application
1.4.1 Overview: Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Diagnostic Center
1.4.4 Other
1.5 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast
1.6 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast by Region
1.6.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region, (2018-2029)
1.6.3 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2018-2029)
1.6.4 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2018-2029)
1.6.6 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Autolus Therapeutics
2.1.1 Autolus Therapeutics Details
2.1.2 Autolus Therapeutics Major Business
2.1.3 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.1.4 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Autolus Therapeutics Recent Developments and Future Plans
2.2 CARsgen Therapeutics
2.2.1 CARsgen Therapeutics Details
2.2.2 CARsgen Therapeutics Major Business
2.2.3 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.2.4 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 CARsgen Therapeutics Recent Developments and Future Plans
2.3 Juno Therapeutics
2.3.1 Juno Therapeutics Details
2.3.2 Juno Therapeutics Major Business
2.3.3 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.3.4 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Juno Therapeutics Recent Developments and Future Plans
2.4 Sorrento Therapeutics
2.4.1 Sorrento Therapeutics Details
2.4.2 Sorrento Therapeutics Major Business
2.4.3 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.4.4 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Sorrento Therapeutics Recent Developments and Future Plans
2.5 bluebird bio
2.5.1 bluebird bio Details
2.5.2 bluebird bio Major Business
2.5.3 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.5.4 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 bluebird bio Recent Developments and Future Plans
2.6 CELGENE CORPORATION
2.6.1 CELGENE CORPORATION Details
2.6.2 CELGENE CORPORATION Major Business
2.6.3 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.6.4 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 CELGENE CORPORATION Recent Developments and Future Plans
2.7 Eureka Therapeutics
2.7.1 Eureka Therapeutics Details
2.7.2 Eureka Therapeutics Major Business
2.7.3 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.7.4 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Eureka Therapeutics Recent Developments and Future Plans
2.8 Avacta Life Sciences
2.8.1 Avacta Life Sciences Details
2.8.2 Avacta Life Sciences Major Business
2.8.3 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.8.4 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Avacta Life Sciences Recent Developments and Future Plans
2.9 Calyxt
2.9.1 Calyxt Details
2.9.2 Calyxt Major Business
2.9.3 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.9.4 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Calyxt Recent Developments and Future Plans
2.10 Celyad Oncology SA
2.10.1 Celyad Oncology SA Details
2.10.2 Celyad Oncology SA Major Business
2.10.3 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.10.4 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Celyad Oncology SA Recent Developments and Future Plans
2.11 Fortress Biotech
2.11.1 Fortress Biotech Details
2.11.2 Fortress Biotech Major Business
2.11.3 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.11.4 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Fortress Biotech Recent Developments and Future Plans
2.12 IMMUNE THERAPEUTICS
2.12.1 IMMUNE THERAPEUTICS Details
2.12.2 IMMUNE THERAPEUTICS Major Business
2.12.3 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.12.4 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 IMMUNE THERAPEUTICS Recent Developments and Future Plans
2.13 Gilead Sciences
2.13.1 Gilead Sciences Details
2.13.2 Gilead Sciences Major Business
2.13.3 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.13.4 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Gilead Sciences Recent Developments and Future Plans
2.14 Novartis AG
2.14.1 Novartis AG Details
2.14.2 Novartis AG Major Business
2.14.3 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.14.4 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Novartis AG Recent Developments and Future Plans
2.15 Alaunos Therapeutics
2.15.1 Alaunos Therapeutics Details
2.15.2 Alaunos Therapeutics Major Business
2.15.3 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.15.4 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Alaunos Therapeutics Recent Developments and Future Plans
2.16 Poseida Therapeutics
2.16.1 Poseida Therapeutics Details
2.16.2 Poseida Therapeutics Major Business
2.16.3 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.16.4 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Poseida Therapeutics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Chimeric Antigen Receptor (CAR)-T Cell Therapy by Company Revenue
3.2.2 Top 3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Players Market Share in 2022
3.2.3 Top 6 Chimeric Antigen Receptor (CAR)-T Cell Therapy Players Market Share in 2022
3.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Overall Company Footprint Analysis
3.3.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Region Footprint
3.3.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Type Footprint
3.3.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value and Market Share by Type (2018-2023)
4.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2018-2023)
5.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2029)
6.2 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2029)
6.3 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country
6.3.1 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2029)
6.3.2 United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
6.3.3 Canada Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
6.3.4 Mexico Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2029)
7.2 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2029)
7.3 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country
7.3.1 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2029)
7.3.2 Germany Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
7.3.3 France Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
7.3.5 Russia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
7.3.6 Italy Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region
8.3.1 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2018-2029)
8.3.2 China Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
8.3.3 Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
8.3.4 South Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
8.3.5 India Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
8.3.7 Australia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2029)
9.2 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2029)
9.3 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country
9.3.1 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2029)
9.3.2 Brazil Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
9.3.3 Argentina Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country
10.3.1 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2029)
10.3.2 Turkey Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
10.3.4 UAE Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Drivers
11.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Restraints
11.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry Chain
12.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Upstream Analysis
12.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Midstream Analysis
12.4 Chimeric Antigen Receptor (CAR)-T Cell Therapy Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Chimeric Antigen Receptor (CAR)-T Cell Therapy
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Chimeric Antigen Receptor (CAR)-T Cell Therapy by Type
1.3.1 Overview: Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type in 2022
1.3.3 Abecma
1.3.4 Breyanzi
1.3.5 Kymriah
1.3.6 Tecartus
1.3.7 Yescarta
1.3.8 Others
1.4 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market by Application
1.4.1 Overview: Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Diagnostic Center
1.4.4 Other
1.5 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast
1.6 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast by Region
1.6.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region, (2018-2029)
1.6.3 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2018-2029)
1.6.4 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2018-2029)
1.6.6 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Autolus Therapeutics
2.1.1 Autolus Therapeutics Details
2.1.2 Autolus Therapeutics Major Business
2.1.3 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.1.4 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Autolus Therapeutics Recent Developments and Future Plans
2.2 CARsgen Therapeutics
2.2.1 CARsgen Therapeutics Details
2.2.2 CARsgen Therapeutics Major Business
2.2.3 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.2.4 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 CARsgen Therapeutics Recent Developments and Future Plans
2.3 Juno Therapeutics
2.3.1 Juno Therapeutics Details
2.3.2 Juno Therapeutics Major Business
2.3.3 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.3.4 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Juno Therapeutics Recent Developments and Future Plans
2.4 Sorrento Therapeutics
2.4.1 Sorrento Therapeutics Details
2.4.2 Sorrento Therapeutics Major Business
2.4.3 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.4.4 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Sorrento Therapeutics Recent Developments and Future Plans
2.5 bluebird bio
2.5.1 bluebird bio Details
2.5.2 bluebird bio Major Business
2.5.3 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.5.4 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 bluebird bio Recent Developments and Future Plans
2.6 CELGENE CORPORATION
2.6.1 CELGENE CORPORATION Details
2.6.2 CELGENE CORPORATION Major Business
2.6.3 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.6.4 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 CELGENE CORPORATION Recent Developments and Future Plans
2.7 Eureka Therapeutics
2.7.1 Eureka Therapeutics Details
2.7.2 Eureka Therapeutics Major Business
2.7.3 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.7.4 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Eureka Therapeutics Recent Developments and Future Plans
2.8 Avacta Life Sciences
2.8.1 Avacta Life Sciences Details
2.8.2 Avacta Life Sciences Major Business
2.8.3 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.8.4 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Avacta Life Sciences Recent Developments and Future Plans
2.9 Calyxt
2.9.1 Calyxt Details
2.9.2 Calyxt Major Business
2.9.3 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.9.4 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Calyxt Recent Developments and Future Plans
2.10 Celyad Oncology SA
2.10.1 Celyad Oncology SA Details
2.10.2 Celyad Oncology SA Major Business
2.10.3 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.10.4 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Celyad Oncology SA Recent Developments and Future Plans
2.11 Fortress Biotech
2.11.1 Fortress Biotech Details
2.11.2 Fortress Biotech Major Business
2.11.3 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.11.4 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Fortress Biotech Recent Developments and Future Plans
2.12 IMMUNE THERAPEUTICS
2.12.1 IMMUNE THERAPEUTICS Details
2.12.2 IMMUNE THERAPEUTICS Major Business
2.12.3 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.12.4 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 IMMUNE THERAPEUTICS Recent Developments and Future Plans
2.13 Gilead Sciences
2.13.1 Gilead Sciences Details
2.13.2 Gilead Sciences Major Business
2.13.3 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.13.4 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Gilead Sciences Recent Developments and Future Plans
2.14 Novartis AG
2.14.1 Novartis AG Details
2.14.2 Novartis AG Major Business
2.14.3 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.14.4 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Novartis AG Recent Developments and Future Plans
2.15 Alaunos Therapeutics
2.15.1 Alaunos Therapeutics Details
2.15.2 Alaunos Therapeutics Major Business
2.15.3 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.15.4 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Alaunos Therapeutics Recent Developments and Future Plans
2.16 Poseida Therapeutics
2.16.1 Poseida Therapeutics Details
2.16.2 Poseida Therapeutics Major Business
2.16.3 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
2.16.4 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Poseida Therapeutics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Chimeric Antigen Receptor (CAR)-T Cell Therapy by Company Revenue
3.2.2 Top 3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Players Market Share in 2022
3.2.3 Top 6 Chimeric Antigen Receptor (CAR)-T Cell Therapy Players Market Share in 2022
3.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Overall Company Footprint Analysis
3.3.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Region Footprint
3.3.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Type Footprint
3.3.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value and Market Share by Type (2018-2023)
4.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2018-2023)
5.2 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2029)
6.2 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2029)
6.3 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country
6.3.1 North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2029)
6.3.2 United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
6.3.3 Canada Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
6.3.4 Mexico Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2029)
7.2 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2029)
7.3 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country
7.3.1 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2029)
7.3.2 Germany Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
7.3.3 France Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
7.3.5 Russia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
7.3.6 Italy Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region
8.3.1 Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2018-2029)
8.3.2 China Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
8.3.3 Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
8.3.4 South Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
8.3.5 India Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
8.3.7 Australia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2029)
9.2 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2029)
9.3 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country
9.3.1 South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2029)
9.3.2 Brazil Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
9.3.3 Argentina Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Country
10.3.1 Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2029)
10.3.2 Turkey Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
10.3.4 UAE Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Drivers
11.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Restraints
11.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry Chain
12.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Upstream Analysis
12.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Midstream Analysis
12.4 Chimeric Antigen Receptor (CAR)-T Cell Therapy Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Autolus Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Autolus Therapeutics Major Business
Table 7. Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 8. Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Autolus Therapeutics Recent Developments and Future Plans
Table 10. CARsgen Therapeutics Company Information, Head Office, and Major Competitors
Table 11. CARsgen Therapeutics Major Business
Table 12. CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 13. CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. CARsgen Therapeutics Recent Developments and Future Plans
Table 15. Juno Therapeutics Company Information, Head Office, and Major Competitors
Table 16. Juno Therapeutics Major Business
Table 17. Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 18. Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Juno Therapeutics Recent Developments and Future Plans
Table 20. Sorrento Therapeutics Company Information, Head Office, and Major Competitors
Table 21. Sorrento Therapeutics Major Business
Table 22. Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 23. Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Sorrento Therapeutics Recent Developments and Future Plans
Table 25. bluebird bio Company Information, Head Office, and Major Competitors
Table 26. bluebird bio Major Business
Table 27. bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 28. bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. bluebird bio Recent Developments and Future Plans
Table 30. CELGENE CORPORATION Company Information, Head Office, and Major Competitors
Table 31. CELGENE CORPORATION Major Business
Table 32. CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 33. CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. CELGENE CORPORATION Recent Developments and Future Plans
Table 35. Eureka Therapeutics Company Information, Head Office, and Major Competitors
Table 36. Eureka Therapeutics Major Business
Table 37. Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 38. Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Eureka Therapeutics Recent Developments and Future Plans
Table 40. Avacta Life Sciences Company Information, Head Office, and Major Competitors
Table 41. Avacta Life Sciences Major Business
Table 42. Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 43. Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Avacta Life Sciences Recent Developments and Future Plans
Table 45. Calyxt Company Information, Head Office, and Major Competitors
Table 46. Calyxt Major Business
Table 47. Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 48. Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Calyxt Recent Developments and Future Plans
Table 50. Celyad Oncology SA Company Information, Head Office, and Major Competitors
Table 51. Celyad Oncology SA Major Business
Table 52. Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 53. Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Celyad Oncology SA Recent Developments and Future Plans
Table 55. Fortress Biotech Company Information, Head Office, and Major Competitors
Table 56. Fortress Biotech Major Business
Table 57. Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 58. Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Fortress Biotech Recent Developments and Future Plans
Table 60. IMMUNE THERAPEUTICS Company Information, Head Office, and Major Competitors
Table 61. IMMUNE THERAPEUTICS Major Business
Table 62. IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 63. IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. IMMUNE THERAPEUTICS Recent Developments and Future Plans
Table 65. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 66. Gilead Sciences Major Business
Table 67. Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 68. Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Gilead Sciences Recent Developments and Future Plans
Table 70. Novartis AG Company Information, Head Office, and Major Competitors
Table 71. Novartis AG Major Business
Table 72. Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 73. Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Novartis AG Recent Developments and Future Plans
Table 75. Alaunos Therapeutics Company Information, Head Office, and Major Competitors
Table 76. Alaunos Therapeutics Major Business
Table 77. Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 78. Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Alaunos Therapeutics Recent Developments and Future Plans
Table 80. Poseida Therapeutics Company Information, Head Office, and Major Competitors
Table 81. Poseida Therapeutics Major Business
Table 82. Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 83. Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Poseida Therapeutics Recent Developments and Future Plans
Table 85. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million) by Players (2018-2023)
Table 86. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Share by Players (2018-2023)
Table 87. Breakdown of Chimeric Antigen Receptor (CAR)-T Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3)
Table 88. Market Position of Players in Chimeric Antigen Receptor (CAR)-T Cell Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 89. Head Office of Key Chimeric Antigen Receptor (CAR)-T Cell Therapy Players
Table 90. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Type Footprint
Table 91. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Application Footprint
Table 92. Chimeric Antigen Receptor (CAR)-T Cell Therapy New Market Entrants and Barriers to Market Entry
Table 93. Chimeric Antigen Receptor (CAR)-T Cell Therapy Mergers, Acquisition, Agreements, and Collaborations
Table 94. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (USD Million) by Type (2018-2023)
Table 95. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Share by Type (2018-2023)
Table 96. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Forecast by Type (2024-2029)
Table 97. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2023)
Table 98. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Forecast by Application (2024-2029)
Table 99. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 100. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 101. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 102. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 103. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 104. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 105. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 106. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 107. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 108. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 109. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 110. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 111. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 112. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 113. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 114. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 115. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2018-2023) & (USD Million)
Table 116. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2024-2029) & (USD Million)
Table 117. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 118. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 119. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 120. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 121. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 122. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 123. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 124. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 125. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 126. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 127. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 128. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 129. Chimeric Antigen Receptor (CAR)-T Cell Therapy Raw Material
Table 130. Key Suppliers of Chimeric Antigen Receptor (CAR)-T Cell Therapy Raw Materials
Table 1. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Autolus Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Autolus Therapeutics Major Business
Table 7. Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 8. Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Autolus Therapeutics Recent Developments and Future Plans
Table 10. CARsgen Therapeutics Company Information, Head Office, and Major Competitors
Table 11. CARsgen Therapeutics Major Business
Table 12. CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 13. CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. CARsgen Therapeutics Recent Developments and Future Plans
Table 15. Juno Therapeutics Company Information, Head Office, and Major Competitors
Table 16. Juno Therapeutics Major Business
Table 17. Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 18. Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Juno Therapeutics Recent Developments and Future Plans
Table 20. Sorrento Therapeutics Company Information, Head Office, and Major Competitors
Table 21. Sorrento Therapeutics Major Business
Table 22. Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 23. Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Sorrento Therapeutics Recent Developments and Future Plans
Table 25. bluebird bio Company Information, Head Office, and Major Competitors
Table 26. bluebird bio Major Business
Table 27. bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 28. bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. bluebird bio Recent Developments and Future Plans
Table 30. CELGENE CORPORATION Company Information, Head Office, and Major Competitors
Table 31. CELGENE CORPORATION Major Business
Table 32. CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 33. CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. CELGENE CORPORATION Recent Developments and Future Plans
Table 35. Eureka Therapeutics Company Information, Head Office, and Major Competitors
Table 36. Eureka Therapeutics Major Business
Table 37. Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 38. Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Eureka Therapeutics Recent Developments and Future Plans
Table 40. Avacta Life Sciences Company Information, Head Office, and Major Competitors
Table 41. Avacta Life Sciences Major Business
Table 42. Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 43. Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Avacta Life Sciences Recent Developments and Future Plans
Table 45. Calyxt Company Information, Head Office, and Major Competitors
Table 46. Calyxt Major Business
Table 47. Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 48. Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Calyxt Recent Developments and Future Plans
Table 50. Celyad Oncology SA Company Information, Head Office, and Major Competitors
Table 51. Celyad Oncology SA Major Business
Table 52. Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 53. Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Celyad Oncology SA Recent Developments and Future Plans
Table 55. Fortress Biotech Company Information, Head Office, and Major Competitors
Table 56. Fortress Biotech Major Business
Table 57. Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 58. Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Fortress Biotech Recent Developments and Future Plans
Table 60. IMMUNE THERAPEUTICS Company Information, Head Office, and Major Competitors
Table 61. IMMUNE THERAPEUTICS Major Business
Table 62. IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 63. IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. IMMUNE THERAPEUTICS Recent Developments and Future Plans
Table 65. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 66. Gilead Sciences Major Business
Table 67. Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 68. Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Gilead Sciences Recent Developments and Future Plans
Table 70. Novartis AG Company Information, Head Office, and Major Competitors
Table 71. Novartis AG Major Business
Table 72. Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 73. Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Novartis AG Recent Developments and Future Plans
Table 75. Alaunos Therapeutics Company Information, Head Office, and Major Competitors
Table 76. Alaunos Therapeutics Major Business
Table 77. Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 78. Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Alaunos Therapeutics Recent Developments and Future Plans
Table 80. Poseida Therapeutics Company Information, Head Office, and Major Competitors
Table 81. Poseida Therapeutics Major Business
Table 82. Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Solutions
Table 83. Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Poseida Therapeutics Recent Developments and Future Plans
Table 85. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (USD Million) by Players (2018-2023)
Table 86. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Share by Players (2018-2023)
Table 87. Breakdown of Chimeric Antigen Receptor (CAR)-T Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3)
Table 88. Market Position of Players in Chimeric Antigen Receptor (CAR)-T Cell Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 89. Head Office of Key Chimeric Antigen Receptor (CAR)-T Cell Therapy Players
Table 90. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Type Footprint
Table 91. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Application Footprint
Table 92. Chimeric Antigen Receptor (CAR)-T Cell Therapy New Market Entrants and Barriers to Market Entry
Table 93. Chimeric Antigen Receptor (CAR)-T Cell Therapy Mergers, Acquisition, Agreements, and Collaborations
Table 94. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (USD Million) by Type (2018-2023)
Table 95. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Share by Type (2018-2023)
Table 96. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Forecast by Type (2024-2029)
Table 97. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2023)
Table 98. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Forecast by Application (2024-2029)
Table 99. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 100. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 101. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 102. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 103. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 104. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 105. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 106. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 107. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 108. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 109. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 110. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 111. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 112. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 113. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 114. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 115. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2018-2023) & (USD Million)
Table 116. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2024-2029) & (USD Million)
Table 117. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 118. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 119. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 120. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 121. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 122. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 123. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 124. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 125. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 126. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 127. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 128. Middle East & Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 129. Chimeric Antigen Receptor (CAR)-T Cell Therapy Raw Material
Table 130. Key Suppliers of Chimeric Antigen Receptor (CAR)-T Cell Therapy Raw Materials
LIST OF FIGURES
Figure 1. Chimeric Antigen Receptor (CAR)-T Cell Therapy Picture
Figure 2. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type in 2022
Figure 4. Abecma
Figure 5. Breyanzi
Figure 6. Kymriah
Figure 7. Tecartus
Figure 8. Yescarta
Figure 9. Others
Figure 10. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 11. Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application in 2022
Figure 12. Hospital Picture
Figure 13. Diagnostic Center Picture
Figure 14. Other Picture
Figure 15. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 16. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 17. Global Market Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 18. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Region (2018-2029)
Figure 19. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Region in 2022
Figure 20. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 21. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 22. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 23. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 24. Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 25. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Share by Players in 2022
Figure 26. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 27. Global Top 3 Players Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share in 2022
Figure 28. Global Top 6 Players Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share in 2022
Figure 29. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Share by Type (2018-2023)
Figure 30. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share Forecast by Type (2024-2029)
Figure 31. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Share by Application (2018-2023)
Figure 32. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share Forecast by Application (2024-2029)
Figure 33. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 34. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 35. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 37. Canada Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 38. Mexico Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 39. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 40. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 41. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Country (2018-2029)
Figure 42. Germany Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 43. France Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 44. United Kingdom Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 45. Russia Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 46. Italy Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 47. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 48. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 49. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Region (2018-2029)
Figure 50. China Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 51. Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 52. South Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 53. India Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 54. Southeast Asia Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 55. Australia Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 56. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 57. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 58. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Country (2018-2029)
Figure 59. Brazil Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 60. Argentina Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 61. Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 62. Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 63. Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Country (2018-2029)
Figure 64. Turkey Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 65. Saudi Arabia Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 66. UAE Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 67. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Drivers
Figure 68. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Restraints
Figure 69. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Manufacturing Cost Structure Analysis of Chimeric Antigen Receptor (CAR)-T Cell Therapy in 2022
Figure 72. Manufacturing Process Analysis of Chimeric Antigen Receptor (CAR)-T Cell Therapy
Figure 73. Chimeric Antigen Receptor (CAR)-T Cell Therapy Industrial Chain
Figure 74. Methodology
Figure 75. Research Process and Data Source
Figure 1. Chimeric Antigen Receptor (CAR)-T Cell Therapy Picture
Figure 2. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type in 2022
Figure 4. Abecma
Figure 5. Breyanzi
Figure 6. Kymriah
Figure 7. Tecartus
Figure 8. Yescarta
Figure 9. Others
Figure 10. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 11. Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application in 2022
Figure 12. Hospital Picture
Figure 13. Diagnostic Center Picture
Figure 14. Other Picture
Figure 15. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 16. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 17. Global Market Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 18. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Region (2018-2029)
Figure 19. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Region in 2022
Figure 20. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 21. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 22. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 23. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 24. Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 25. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Share by Players in 2022
Figure 26. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 27. Global Top 3 Players Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share in 2022
Figure 28. Global Top 6 Players Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share in 2022
Figure 29. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Share by Type (2018-2023)
Figure 30. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share Forecast by Type (2024-2029)
Figure 31. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Share by Application (2018-2023)
Figure 32. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Share Forecast by Application (2024-2029)
Figure 33. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 34. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 35. North America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 37. Canada Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 38. Mexico Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 39. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 40. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 41. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Country (2018-2029)
Figure 42. Germany Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 43. France Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 44. United Kingdom Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 45. Russia Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 46. Italy Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 47. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 48. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 49. Asia-Pacific Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Region (2018-2029)
Figure 50. China Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 51. Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 52. South Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 53. India Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 54. Southeast Asia Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 55. Australia Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 56. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 57. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 58. South America Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Country (2018-2029)
Figure 59. Brazil Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 60. Argentina Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 61. Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 62. Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 63. Middle East and Africa Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Country (2018-2029)
Figure 64. Turkey Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 65. Saudi Arabia Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 66. UAE Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 67. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Drivers
Figure 68. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Restraints
Figure 69. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Trends
Figure 70. Porters Five Forces Analysis
Figure 71. Manufacturing Cost Structure Analysis of Chimeric Antigen Receptor (CAR)-T Cell Therapy in 2022
Figure 72. Manufacturing Process Analysis of Chimeric Antigen Receptor (CAR)-T Cell Therapy
Figure 73. Chimeric Antigen Receptor (CAR)-T Cell Therapy Industrial Chain
Figure 74. Methodology
Figure 75. Research Process and Data Source
